Name

Miles Congreve, PhD

Title

Chief Scientific Officer

Miles is our Chief Scientific Officer. He has helped design 29 clinically evaluated drugs and is co-inventor of Kisqali® (Ribociclib), a marketed treatment for breast cancers.

As Chief Scientific Officer at Sosei Heptares, Miles pioneered Structure-Based Drug Design for G Protein-Coupled Receptors (GPCRs). As Director of Chemistry at Astex Pharmaceuticals, he helped establish Fragment-Based Drug Design as a radical new approach to small molecule lead generation. He has also been a team leader at GlaxoSmithKline in medicinal chemistry and chemical technologies.

In 2025 Miles was recognised in the TIME 100 AI list as one of the world’s most influential people in AI. He is co-author of over 200 publications and patents and a fellow of the Royal Society of Chemistry. In 2015, he was co-recipient of the RSC Malcolm Campbell Memorial Prize for the seminal contributions to GPCR drug discovery made by Sosei Heptares.

Miles has a degree in biological chemistry from Leicester University and a PhD in synthetic chemistry from Cambridge University.

“After more than 25 years working in drug discovery I can say that we get things wrong more times than we get them right. At Isomorphic Labs we are using everything we know in life sciences in order to make better predictions, improve decision-making and transform the medicine design process. I feel privileged to work with a team with the focus and passion to deliver on this vision.”